




OBJECTIVES

The aim of this study is to evaluate overall survival of patients treated with Tocilizumab and the factors that influence survival. In addition, the marginal cost of treatment with Tocilizumab is analyzed.

MATERIALS AND METHODS



RESULTS



Subgrupo	n	RMST (years)	MC/RMST (€/year)	MC/YLG(€)	CM/SV(€)
Global	508	0,761	534,07	530 €	552 €
Severity					
UCI	87	0,676	654,51	666 €	675 €
Non-UCI	421	0,764	532,81	579 €	551 €
Age					
Older than 71,5	199	0,581	697,84	701 €	726 €
Younger than 71,5	309	0,872	466,82	467 €	477 €

CONCLUSIONS

Treatment with Tocilizumab in patients with COVID-19 is more effective in patients admitted to the non-ICU vs. ICU. In addition, survival is higher in younger patients aged 71.5 years. The mean cost of treatment with Tocilizumab was €534.07/year